Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
Sculier D, Calmy A, Egger M, Limacher A, Schmid P, Günthard H, Decosterd L, Metzner K, Buzzi M, Cavassini M, Veraguth K, Braun D, Bernasconi E, Stoeckle M, Marinosci A, Yerly S, Wandeler G, and the Swiss HIV Cohort Study (SHCS). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. PLoS Med 2020; 17:e1003421.
10.11.2020
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
10.11.2020
PLoS Med 2020; 17:e1003421
Sculier Delphine, Calmy Alexandra, Egger Matthias, Limacher Andreas, Schmid Patrick, Günthard Huldrych F, Decosterd Laurent A, Metzner Karin J, Buzzi Marta, Cavassini Matthias, Veraguth Katja, Braun Dominique L, Bernasconi Enos, Stoeckle Marcel, Marinosci Annalisa, Yerly Sabine, Wandeler Gilles, and the Swiss HIV Cohort Study (SHCS)
Weiter
